Liver Cancer

Opdivo (nivolumab) was granted a priority review designation by the Food and Drug Administration (FDA) to treat some patients with liver cancer.

The Food and Drug Administration (FDA) has approved Stivarga as a second-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who have previously received Nexavar.

Understanding liver cancer is a crucial step toward the prevention of this rare condition.

Liver cancer diagnoses and mortality have been rising, but new treatments are designed to help reverse the trend.

A recent phase 3 trial showed that treatment with Lenvima is noninferior to standard treatment for patients with unresectable liver cancer.

Stivarga was granted a priority review by the FDA to treat certain patients with liver cancer in the second line setting.

Stivarga is being considered by the FDA for approval for second-line liver cancer treatment, renewing hope in the field.

After doing well in a phase 3 trial, Stivarga showed the potential to shift the treatment paradigm for previously treated liver cancer.

Michael Choti talks about what kind of advances can be expected in treating liver cancer, including PD-1 inhibitors and neoadjuvant treatment.

The number 18 holds special meaning for me as it marks 18 years since I heard these words: “You have incurable colon cancer.”

Morris Sherman discusses finding second-line treatments for patients with HCC.

The incidence of NASH-associated liver cancer is growing, prompting researchers to further investigate this subset of patients.

CURE spoke with Ghassan K. Abou-Alfa about the potential of using a vaccinia to treat advanced HCC.